Beneficial effects of embryo extract on cultured rabbit cartilage cells

For several decades, it has been known that oestrogens are essential for human health. The discovery that there are two oestrogen receptors (ERs), ERalpha and ERbeta, has facilitated our understanding of how the hormone exerts its physiological effects. The ERs belong to the family of ligand-activated nuclear receptors, which act by modulating the expression of target genes. Studies of ER-knockout (ERKO) mice have been instrumental in defining the relevance of a given receptor subtype in a certain tissue. Phenotypes displayed by ERKO mice suggest diseases in which dysfunctional ERs might be involved in aetiology and pathology. Association between single-nucleotide polymorphisms (SNPs) in ER genes and disease have been demonstrated in several cases. Selective ER modulators (SERMs), which are selective with regard to their effects in a certain cell type, already exist. Since oestrogen has effects in many tissues, the goal with a SERM is to provide beneficial effects in one target tissue while avoiding side effects in others. Refined SERMs will, in the future, provide improved therapeutic strategies for existing and novel indications.

Download Full-text

ACE2 as therapeutic agent

Clinical Science ◽

10.1042/cs20200570 ◽

2020 ◽

Vol 134 (19) ◽

pp. 2581-2595

Author(s):

Qiuhong Li ◽

Maria B. Grant ◽

Elaine M. Richards ◽

Mohan K. Raizada

Keyword(s):

Therapeutic Agent ◽

Renin Angiotensin System ◽

Peptide Hormone ◽

Experimental Models ◽

Electrolyte Balance ◽

Ang Ii ◽

Angiotensin Converting Enzyme 2 ◽

Beneficial Effects ◽

Overwhelming Evidence ◽

Future Challenges

Abstract The angiotensin-converting enzyme 2 (ACE2) has emerged as a critical regulator of the renin–angiotensin system (RAS), which plays important roles in cardiovascular homeostasis by regulating vascular tone, fluid and electrolyte balance. ACE2 functions as a carboxymonopeptidase hydrolyzing the cleavage of a single C-terminal residue from Angiotensin-II (Ang-II), the key peptide hormone of RAS, to form Angiotensin-(1-7) (Ang-(1-7)), which binds to the G-protein–coupled Mas receptor and activates signaling pathways that counteract the pathways activated by Ang-II. ACE2 is expressed in a variety of tissues and overwhelming evidence substantiates the beneficial effects of enhancing ACE2/Ang-(1-7)/Mas axis under many pathological conditions in these tissues in experimental models. This review will provide a succinct overview on current strategies to enhance ACE2 as therapeutic agent, and discuss limitations and future challenges. ACE2 also has other functions, such as acting as a co-factor for amino acid transport and being exploited by the severe acute respiratory syndrome coronaviruses (SARS-CoVs) as cellular entry receptor, the implications of these functions in development of ACE2-based therapeutics will also be discussed.

Download Full-text

44 Beneficial effects of pharmacological enhancement of the endothelial NO synthases on cardiac function and hypertrophy in an animal model of heart failure despite normal EF

European Journal of Heart Failure Supplements ◽

10.1016/s1567-4215(07)60010-1 ◽

2007 ◽

Vol 6 (1) ◽

pp. 4-4

Author(s):

D WESTERMANN ◽

S JAEGER ◽

A RIAD ◽

U RICHTER ◽

H SCHULTHEISS ◽

...

Keyword(s):

Heart Failure ◽

Animal Model ◽

Cardiac Function ◽

Beneficial Effects

Download Full-text

174 Early beneficial effects of vasopeptidase inhibtion n an experimental model of heart failure

European Journal of Heart Failure Supplements ◽

10.1016/s1567-4215(03)90103-2 ◽

2003 ◽

Vol 2 (1) ◽

pp. 33-34

Author(s):

B SHIVALKAR ◽

B MEURIS ◽

R VANBENEDEN ◽

J KETESLEGERS ◽

F BECKERS ◽

...

Keyword(s):

Heart Failure ◽

Experimental Model ◽

Beneficial Effects

Download Full-text

293 Late beneficial effects of a disease program management on mortality, hospitalisation, and quality of life in heart failure patients

European Journal of Heart Failure Supplements ◽

10.1016/s1567-4215(07)60172-6 ◽

2007 ◽

Vol 6 (1) ◽

pp. 63-63

Author(s):

E BOCCHI ◽

F CRUZ ◽

G GUIMARAES ◽

F BACAL ◽

G DOUSA ◽

...

Keyword(s):

Quality Of Life ◽

Heart Failure ◽

Program Management ◽

Heart Failure Patients ◽

Beneficial Effects

Download Full-text

Association of Vitamin D Status With Liver and Kidney Disease: A Systematic Review of Clinical Trials, and Cross-Sectional and Cohort Studies

International Journal for Vitamin and Nutrition Research ◽

10.1024/0300-9831/a000540 ◽

2019 ◽

pp. 1-13 ◽

Cited By ~ 2

Author(s):

Seyed Mostafa Parizadeh ◽

Majid Rezayi ◽

Reza Jafarzadeh-Esfehani ◽

Amir Avan ◽

Hamideh Ghazizadeh ◽

...

Keyword(s):

Vitamin D ◽

Kidney Disease ◽

Renal Disease ◽

Cohort Studies ◽

Cochrane Library ◽

Major Public Health Problem ◽

Vitamin D Status ◽

Cross Sectional ◽

Beneficial Effects ◽

Vitamin D Levels

Abstract. Background: Vitamin D deficiency (VDD) is a major public health problem. There are few comprehensive systematic reviews about the relationship between Vitamin D status and liver and renal disease in Iran. Methods: We systemically searched the following databases: Web of Science; PubMed; Cochrane Library; Scopus; Science Direct; Google Scholar and two Iranian databases (Scientific Information Database (SID) and IranMedex) up until November 2017 to identify all randomized control trials (RCTs), case control, cross-sectional and cohort studies investigating the association between vitamin D and any form of liver or kidney disease. Results: Vitamin D insufficiency, or deficiency (VDD), is highly prevalent in Iran, reports varying between 44.4% in Isfahan to 98% in Gorgan. There is also a high prevalence of VDD among patients with liver or kidney disease, and the administration of vitamin D supplements may have beneficial effects on lipid profile, blood glucose, liver function and fatty liver disease, and bone health. Low serum vitamin D levels are related with abnormalities in these laboratory and clinical parameters. Conclusion: VDD is prevalent in patients with chronic liver or renal disease in Iran. There appear to be several beneficial effects of vitamin D supplementation in vitamin D deficient patients with liver or kidney disease.

Download Full-text